# Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology

**Authors:** Almohanad A. Alkayyal

PMC · DOI: 10.3389/fmolb.2025.1615393 · Frontiers in Molecular Biosciences · 2025-05-22

## TL;DR

This review explores how studying naturally occurring animal cancers can improve oncolytic virus therapies for both pets and people.

## Contribution

The paper emphasizes the use of veterinary models to advance oncolytic virotherapy through comparative oncology.

## Key findings

- Naturally occurring tumors in animals provide valuable insights for OV-based immunotherapy.
- Comparative analysis of immune responses across species aids in OV therapy development.
- Precision medicine approaches in veterinary oncology enhance OV translation to clinical use.

## Abstract

Cancer is a complex disease affecting both humans and animals. Comparative immuno-oncology explores immune responses across species to develop effective cancer therapies. Oncolytic viruses (OVs) serve as both direct tumor-lysing agents and immune stimulants, making them an attractive therapeutic option. This review highlights the role of naturally occurring tumors in animal models for OV-based cancer immunotherapy. We examine immune responses in different species, the latest advancements in OV therapy, and the role of precision medicine in veterinary oncology. Understanding these comparative aspects enhances OV translation from preclinical to clinical applications in both veterinary and human oncology.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12137337/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12137337/full.md

---
Source: https://tomesphere.com/paper/PMC12137337